Blis Technologies has posted a 25% increase in revenue to $6 million for the six months to September 30 compared with the same period last year.
In an update to NZX yesterday, the company said it had benefited from a clear focus on the key growth drivers of the business, built around its two “hero” ingredients, Blis K12 and Blis M18.
An unaudited net surplus for the first half of the 2025 financial year (1HY25) of $200,000 compared with a loss of $700,000 for the same period last year. Ebitda was $300,000 which compared to a loss of $600,000 for the same period last year.
The net surplus and ebitda for 1HY25 were both stated after inclusion of $300,000 of expenditure to update for China market access regulation changes. Net cash inflow from operating activities was $700,000. Cash and cash equivalents and short-term deposit balances were $8.9m as at September 30.
In late September, Blis became aware a key customer had filed a patent for the Blis K12 and Blis M18 fermentation process in three key jurisdictions. The patent application contained confidential Blis information which had been provided under non-disclosure agreements.
It had taken legal advice and was working to have these matters resolved, Blis said. — APL
